Recent Advances in Cancer Immunotherapy - Kids Too? - Enduring
The field of cancer immunotherapy is advancing fast and requires frequent updates; application of the principles of cancer immunotherapy from adult to pediatric malignancies is also valuable. Immunotherapy is not curing all malignancies currently and many guiding principles of immunotherapy using various modalities have been evaluated in adult malignancies. Pediatric malignancies are less common and, therefore, a longer time is required before sufficient number of patients have been treated to achieve statistically significant results. Updates regarding the current state of immunotherapy for adult malignancies can inform clinical trial design and patient management for pediatric malignancies.
Pediatric Hematology/Oncology Physicians, Advance Practice Practitioners, staff and research team.
- Demonstrate an understanding of basic concepts of cancer immunotherapy.
- Identify the settings in which unique approaches can be applied, e.g. intratumoral therapy.
- Assess the pros and cons of various combination therapies.
- Describe the gaps in pediatric malignancy immunotherapy.
This activity has been planned and implemented in strict compliance with the accreditation requirements, standards, and policies of the ACCME. City of Hope takes responsibility for the content, quality and scientific integrity of this CME activity.
As an accredited CME provider City of Hope requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse that could create a conflict of interest. Any potential conflicts relative to the previous disclosure have been resolved.
Presenter: Dr. Kim Margolin has indicated that she is a Consultant for Checkmate Pharmaceuticals; ImaginAb; Iovance; OncoSec; Pfizer; Tentarix; and Werewolf Therapeutics.
City of Hope further encourages faculty/ authors to identify investigational products or off-label uses of products regulated by the U.S. Food and Drug Administration, at first mention and where appropriate in the content.
The information and opinions presented in this activity do not constitute medical or legal advice. Health care providers must exercise their own professional judgment in their clinical practice, and when confronted with the issues discussed herein, should not substitute this curriculum for the advice of legal counsel or application of sound ethical principles.
Recent Advances in Cancer Immunotherapy - Kids Too? - Enduring has received no commercial support.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this Recent Advances in Cancer Immunotherapy - Kids Too? - Enduring for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Attendance